Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

tacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the expected dosing of the fourth cohort of patients; the collection and use of immunological data to indicate efficacy of the compound; the number of cohorts and patients and the expected dosing amounts in the Phase 1 trial; successful completion of the Phase 1 trial; the launching of a Phase 2 clinical trial in patients with cervical intraepithelial neoplasia (CIN); the possibility of a second Phase 2 trial in HIV-positive low-grade CIN patients.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that we will not be able to recruit patients for our trials in a ti
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- This is a professional ... Heparin sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) ... of Heparin sodium (CAS 9041-08-1) & calcium (CAS ... The report then explores global and China,s top ... (CAS 37270-89-6) listing their product specification, capacity, production ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/30/2014)... California , July 30, 2014 ... technology and CUDA programming expertise to big data, ... markets  eInfochips, a leading engineering R&D ... clients to develop NVIDIA GPU-powered solutions for ... high-performance computing (HPC), industrial , ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Reportlinker.com announces that a new market research ... Pharmaceuticals: Global Industry Guide ... Pharmaceuticals: Global Industry Guide is ... analysis covering the Pharmaceuticals industry. It includes ...
... 2012 Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE ... three lead drugs (Zertane™ completed two phase ... licensing distribution of these drugs and engaged in further ... interim review of the first 50% of patients enrolled ...
Cached Medicine Technology:Pharmaceuticals: Global Industry Guide 2Pharmaceuticals: Global Industry Guide 3Pharmaceuticals: Global Industry Guide 4Pharmaceuticals: Global Industry Guide 5Pharmaceuticals: Global Industry Guide 6Pharmaceuticals: Global Industry Guide 7Pharmaceuticals: Global Industry Guide 8Pharmaceuticals: Global Industry Guide 9Pharmaceuticals: Global Industry Guide 10Pharmaceuticals: Global Industry Guide 11Pharmaceuticals: Global Industry Guide 12Pharmaceuticals: Global Industry Guide 13Pharmaceuticals: Global Industry Guide 14Pharmaceuticals: Global Industry Guide 15Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 2Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 3Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 4
(Date:7/30/2014)... Rancho Cucamonga, CA (PRWEB) July 30, 2014 ... career learning how to make millions. However, like most people, ... all. Determined to find a better way, Paul carefully ... lasting wealth and those who do not. Based on the ... learned to not only improve his life and health, but ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... -- It can happen in an instant: A small child ... and gets critically injured when the furniture tips over. ... around their homes and imagine what could tip over, fall ... than it becoming a reality," Dr. Alex Rosenau, president of ... news release. Between 2009 and 2011, roughly 43,000 people ...
(Date:7/30/2014)... cancer as well as evolutionary changes in a living ... randomly throughout the genome. , However, recent studies have ... multiple mutations that arise simultaneously and in close proximity ... frequently found in regions where chromosomal rearrangements take place. ... Reports , may one day lead to new cancer ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2
... macular degeneration, also called juvenile macular degeneration, is an ... This condition results from a defect in the ABCR ... that removes all-trans-retinaldehyde, a vision byproduct, from retinal rods ... epithelium (RPE), a layer of cells near the retina. ...
... inflammatory condition of the bladder wall. It typically affects ... men. Investigators are testing the bacteria Bacillus Calmette-Guerin(BCG), which ... treating interstitial cystitis, by inserting six installations into the ... study of BCG// also showed that 60 percent of ...
... a screening of the colon do not go through ... procedure that is currently available involves inserting a flexible ... requires anaesthesia and there's a remote chance that the ... patients now have an easier option with the discovery ...
... worldwide and its incidence is high in the Asian and ... foodstuffs. The cancer is also becoming prevalent in the United ... gene activity in liver tumors using the new 'gene chip' ... They found that there is a difference between// those tumors ...
... has shown that infants born during night time have ... to those born during day time. Previous studies have ... weekends and holidays have an increased risk of death ... experienced staff for better obstetric and neonatal care during ...
... Vitamin C has been believed, over the years, to be a ... proved to be true by researchers who have studied changes in ... their study of 12 healthy subjects who took one gram of ... immune system response in all of them during the period. Their ...
Cached Medicine News:
... Sophisticated, moderate-sized CO2 incubator with 6-sided ... walls, and a lighter-weight incubator with ... or water-jacketed designs. HEPA filtered CO2 ... inner door, and fanless, convection air ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
... 240 is a basic portable system for ... results can be obtained when used with ... electrode. • Fast and easy one- and ... for five buffers (pH 1.68, 4.00, 7.00, ...
... 12 shelves. Over-sized compressor. Triple pane thermal ... Self-Contained System No plumbing required. Equipped ... Year Warranty on Parts & Labor and an ... Also available as a chromatography unit which includes ...
Medicine Products: